These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33491528)

  • 41. Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease.
    Aller R; Laserna C; Rojo MÁ; Mora N; García Sánchez C; Pina M; Sigüenza R; Durà M; Primo D; Izaola O; de Luis D
    Rev Esp Enferm Dig; 2018 Oct; 110(10):634-640. PubMed ID: 30032630
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
    Mansour A; Mohajeri-Tehrani MR; Samadi M; Qorbani M; Merat S; Adibi H; Poustchi H; Hekmatdoost A
    Nutr J; 2021 Apr; 20(1):35. PubMed ID: 33838673
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Zafeiriadou E; Patsiaoura K; Katsiki E; Deretzi G; Zavos C; Tsarouchas G; Rakitzi P; Slavakis A
    J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):498-503. PubMed ID: 21436212
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease.
    Ye FZ; Liu WY; Zheng KI; Pan XY; Ma HL; Wang XD; Chen YP; Zheng MH
    Eur J Gastroenterol Hepatol; 2020 Jan; 32(1):80-86. PubMed ID: 31625959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of pomegranate extract on anthropometric indices, serum lipids, glycemic indicators, and blood pressure in patients with nonalcoholic fatty liver disease: A randomized double-blind clinical trial.
    Goodarzi R; Jafarirad S; Mohammadtaghvaei N; Dastoorpoor M; Alavinejad P
    Phytother Res; 2021 Oct; 35(10):5871-5882. PubMed ID: 34498307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease.
    Poulsen MK; Nellemann B; Stødkilde-Jørgensen H; Pedersen SB; Grønbæk H; Nielsen S
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1637-46. PubMed ID: 26829441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress.
    Farhangi MA; Alipour B; Jafarvand E; Khoshbaten M
    Arch Med Res; 2014 Oct; 45(7):589-95. PubMed ID: 25450583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective Effects of Chaihu Shugan San () on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance.
    Jiang WN; Li D; Jiang T; Guo J; Chen YF; Wang J; Zhou Y; Yang CY; Tang CP
    Chin J Integr Med; 2018 Feb; 24(2):125-132. PubMed ID: 27164963
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
    Akaslan SB; Degertekin CK; Yilmaz G; Cakir N; Arslan M; Toruner FB
    Metab Syndr Relat Disord; 2013 Aug; 11(4):243-50. PubMed ID: 23544853
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
    Marchesini G; Brizi M; Bianchi G; Tomassetti S; Bugianesi E; Lenzi M; McCullough AJ; Natale S; Forlani G; Melchionda N
    Diabetes; 2001 Aug; 50(8):1844-50. PubMed ID: 11473047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation.
    Cui CX; Deng JN; Yan L; Liu YY; Fan JY; Mu HN; Sun HY; Wang YH; Han JY
    J Ethnopharmacol; 2017 Aug; 208():24-35. PubMed ID: 28648927
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.
    Erkan G; Sayın I; Polat FB; Çorakçı A; Ataç GK; Değertekin H
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():63-8. PubMed ID: 25910371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis.
    Hu H; Wang J; Li X; Shen L; Shi D; Meng J
    Curr Pharm Des; 2021; 27(29):3235-3243. PubMed ID: 33719959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
    Wah Kheong C; Nik Mustapha NR; Mahadeva S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats.
    Yin Y; Liu H; Zheng Z; Lu R; Jiang Z
    Biomed Pharmacother; 2019 Mar; 111():1290-1296. PubMed ID: 30841442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.
    Mager DR; Yap J; Rodriguez-Dimitrescu C; Mazurak V; Ball G; Gilmour S
    Nutr Clin Pract; 2013 Feb; 28(1):101-11. PubMed ID: 23042833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
    Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
    J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 60. A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease.
    Mahmoudi L; Asadi S; Al-Mousavi Z; Niknam R
    Clin Nutr; 2021 May; 40(5):2999-3005. PubMed ID: 33341312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.